Monoclonal Antibodies

 
 
 

Immunotherapy

Haematologic Malignancies

Solid Organ Malignancies

Other

 
 
Login or Register to unlock everything MedSchool has to offer!
 
 

TDM1

 
 
  •  
    IV infusion
    Trastuzumab-Emtansine
    Kadcyla 
    • Mechanism of Action
    • Contains a monoclonal antibody directed toward HER2 (trastuzumab), linked to a chemotherapeutic agent (DM1), allowing for targeted delivery of cytotoxic chemotherapy to HER2-positive tumour cells.
    • Trastuzumab inhibits HER2 signalling pathways resulting in cell cycle arrest, and also mediates antibody-dependent cell-mediated cytotoxicity.
    • DM1 is a cytotoxic agent that binds to tubulin, preventing polymerisation and resulting in cell cycle arrest in the G2/M phase.
Clinical Use
    • Indication
    • HER2-positive metastatic breast cancer refractory to trastuzumab.
    • Adverse Effects
    • Bone marrow suppression – leucopaenia, anaemia, thrombocytopaenia
    • Immunosuppression (susceptibility to infection)
    • Nausea / vomiting / diarrhoea
    • Abdominal pain
    • Cardiac dysfunction
    • Dyspnoea / wheeze
    • Peripheral neuropathy
    • Arthralgias / myalgias
    • LFT derangement
    • Headache
    • Dizziness
    • Flushing
    • Weight loss
    • Insomnia
    • Rash
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback